Home / Catalogue/ Metabolic/ AOD 9604

MetabolicIn StockSubQ injection

AOD 9604

Peptide fragment · GH C-terminus (176–191) · Synthetic

Half-life

~15-30min

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

room temp

Storage (Reconstituted)

4–6 weeks

Refrigerate at 2-8C

Known For

Modified fragment of HGH (amino acids 176-191). Specifically targets fat metabolism without the growth-promoting effects of full HGH. Stimulates lipolysis and inhibits lipogenesis.

Mechanism of Action

Modified HGH fragment (aa 177-191). Proposed to stimulate lipolysis without HGH's growth/diabetogenic effects. Evidence very weak.

Body vs. External Supply

🟡 Natural/Topping Up

Brand / Trade Names

No pharmaceutical brand Sold as research peptide only FDA GRAS status for food use

Typical Research Dosage

250-500mcg/day SubQ. Some protocols use 300mcg morning fasted.

Vial Duration Guide

5mg vial at 300mcg/day = ~17 days. 10mg vial = ~33 days.

Recommended Vial Size

★ 5mg vials At 300mcg/day, 5mg = ~17 days ✓. 2mg = 7 days (wasteful). 10mg = 33 days (borderline but OK).

Time to Effects

EARLY: 4-6 weeks FULL: 12-16 weeks AOD works subtly — don't expect the dramatic appetite suppression of GLP-1 agonists. Week 2-4: No obvious changes. Working at cellular level on fat metabolism. Week 4-8: Mild reduction in stubborn fat areas may begin. Improved body composition. Week 12-16: Cumulative fat loss becomes noticeable, especially in abdominal area. Minimum commitment: 8-12 weeks. Results are modest compared to GLP-1 agonists. Best as part of a stack, not standalone.

Contraindications & Do Not Combine

No strict contraindications with other peptides on this list.

Common Side Effects

Injection site irritation, headache (reported). Limited safety data from human trials.

Drug Interactions

No significant known interactions (limited data)

Reversibility

Fully reversible — short half-life, no feedback loop disruption

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Heffernan et al. (2001) Obes Res 9(3):179-86 — GH fragment lipolysis in rodents • Stier et al. (2013) — Cartilage regeneration properties • FDA GRAS status granted for food use (2015), NOT FDA APPROVED as injectable therapeutic • Limited human clinical data available

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

Lyophilized: room temp. Reconstituted: 2-8°C, use within 14-21 days.

State	Condition	Duration
Lyophilised (sealed)	room temp	12-24 months
Reconstituted	2-8C	4–6 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Video Resources

AOD 9604 discussed by researchers & practitioners

Independent educational content from researchers, clinicians, and science communicators. Not affiliated with Pepnerd — provided as supplementary reading.

Educational resources only. The videos above are independent third-party content from researchers, clinicians, and science communicators. Pepnerd is not affiliated with any of these creators and does not endorse or make any claims based on their content. All products are sold strictly for in-vitro scientific research.

Select Vial Size

$55.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	~15-30 minutes (very short)
Delivery	SubQ injection
Typical dose	250-500mcg/day
Storage (lyoph.)	room temp
Storage (recon.)	4–6 weeks
Endogenous?	Natural/Topping Up
Suppression	None known
WADA	Prohibited (S0)
FDA status	Category 2 (2023)